[1]陈 莉a,张丛丛a,李青山b,等.AML 和ALL 患者骨髓DNMT1，SFRP1 基因甲基化及其与临床病理特征和预后相关性研究[J].现代检验医学杂志,2022,37(06):7-13.[doi:10.3969/j.issn.1671-7414.2022.06.002]
　CHEN Lia,ZHANG Cong-conga,LI Qing-shanb,et al.Methylation of DNMT1 and SFRP1 Gene in Bone Marrow and Its Correlation with Clinicopathological Features and Prognosis in Patients with AML and ALL[J].Journal of Modern Laboratory Medicine,2022,37(06):7-13.[doi:10.3969/j.issn.1671-7414.2022.06.002]
点击复制

AML 和ALL 患者骨髓DNMT1，SFRP1 基因甲基化及其与临床病理特征和预后相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年06期
页码:
7-13
栏目:
论著
出版日期:
2022-11-15

文章信息/Info

Title:
Methylation of DNMT1 and SFRP1 Gene in Bone Marrow and Its Correlation with Clinicopathological Features and Prognosis in Patients with AML and ALL
文章编号:
1671-7414(2022)06-007-07
作者:
陈 莉a; 张丛丛a; 李青山b; 索晓慧a; 吉慧娟a; 刘洪峰a
(邯郸市中心医院a. 血液内科；b. 骨科，河北邯郸 056001)
Author(s):
CHEN Lia;  ZHANG Cong-conga;  LI Qing-shanb;  SUO Xiao-huia;  JI Hui-juana;  LIU Hong-fenga
(a.Department of Hematology; b.Department of Orthopedics, Handan Central Hospital, Hebei Handan 056001, China)
关键词:
恶性血液病; DNA 甲基化转移酶1(DNMT1); 分泌型卷曲相关蛋白1 (SFRP1); 基因甲基化
分类号:
R557；R446，11
DOI:
10.3969/j.issn.1671-7414.2022.06.002
文献标志码:
A
摘要:
目的 检测急性髓系白血病(acute myeloid leukemia，AML)和急性淋巴细胞白血病(acute lymphoblastic leukemia，ALL)患者骨髓中DNA 甲基化转移酶1(DNA methyltransferase 1，DNMT1)、分泌型卷曲相关蛋白1(secretedfrizzled related protein 1, SFRP1)基因甲基化及 mRNA 表达水平，探讨其与临床病理特征和预后的关系。方法 根据FBA (French-American-British classification systems；法- 美- 英分型系统) 标准选取2019 年11 月～ 2020 年11 月于邯郸市中心医院新诊断的急性白血病患者70 例，其中AML 50 例和ALL 20 例；另选取65 例非恶性血液病患者作为正常对照组。用甲基化特异性聚合酶链式反应(methylation-specific PCR，MSP) 检测所有研究对象骨髓标本中DNMT1 和SFRP1 基因甲基化状态，并分析两基因甲基化与AML 和ALL 患者临床参数之间的关系；用实时定量 PCR 检测所有研究对象化疗前和化疗缓解后骨髓标本中 DNMT1，SFRP1 和β-catenin mRNA 表达；Pearson 相关分析明确DNMT1，SFRP1 和β-catenin mRNA 水平之间的相关性；对所有患者进行随访，比较DNMT1 和SFRP1 基因甲基化与预后的关系。结果 AML 和ALL 患者中DNMT1 基因甲基化发生率分别为26.0% 和25.0%，较对照组(73.8%)显著下降(χ2=47.683，P ＜ 0.001)；SFRP1 基因甲基化发生率分别为78.0% 和85.0%，较正常对照组(18.5%)显著增加(χ2=55.265，P ＜ 0.001)，差异均有统计学意义。AML 组DNMT1 基因甲基化与WBC 水平、遗传学预后分组有明显相关性(χ2=6.524，5.732，均P ＜ 0.001)；SFRP1 基因甲基化与WBC 水平、BM 水平和遗传学预后分组有明显相关性(χ2=8.115, 5.395, 5.060，均P＜ 0.05)。ALL 组DNMT1 基因甲基化只与遗传学预后分组有关(χ2=4.802，P ＜ 0.05)；SFRP1 基因甲基化与WBC 水平、遗传学预后分组有明显相关性(χ2=4.920, 5.115，均P ＜ 0.05)。与对照组相比，AML 和ALL 患者化疗前DNMT1 和β-catenin mRNA 表达均显著升高(t=4.807 ～ 10.456，均P＜ 0.05)，SFRP1 表达显著下降(t=24.791，12.069，均P＜ 0.05)。与化疗前相比，AML 和ALL 患者化疗后DNMT1 和β-catenin mRNA 表达显著下降(t=3.461 ～ 6.374，均P ＜ 0.05)，SFRP1 表达显著上升(t=17.076，7.454，P ＜ 0.05)。两组患者DNMT1 与SFRP1 表达呈明显负相关(r=-0.328，-0.315，均P ＜ 0.05)；SFRP1 与β-catenin 表达呈明显正相关(r=0.682，0.728，均P ＜ 0.05)；两组患者DNMT1与β-catenin 表达均无明显相关性。两组患者DNMT1 基因甲基化生存率高于其未甲基化生存率(χ2=3.862，3.679，均P ＜ 0.05)；SFRP1 基因甲基化生存率低于其未甲基化生存率(χ2=2.927，3.155，均P ＜ 0.05)。结论 DNMT1 和SFRP1 基因甲基化与恶性血液病患者临床病理及预后相关，究其原因可能与DNMT1 和SFRP1 基因甲基化异常激活Wnt/β-catenin 信号通路有关。
Abstract:
Objective To detect the levels of DNA methyltransferase 1 (DNMT1) secretory frizzled related protein 1 (SFRP1) gene methylation and mRNA expression in bone marrow of patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), and explore their relationship with clinicopathological characteristics and prognosis. Methods From November 2019 to November 2020, 70 patients with newly diagnosed acute leukemia in Handan Central Hospital were selected according to FBA (French-American-British classification systems)criteria, including 50 patients with AML and 20 patients with ALL. Another 65 patients with non-malignant hematologic diseases were selected as normal control group. Methylation-specific PCR (MSP) was used to detect the methylation status of DNMT1 and SFRP1 genes in bone marrow samples of ALL subjects, and the relationship between methylation of DNMT1 and SFRP1 genes and clinical parameters of AML and ALL patients was analyzed. Real time quantitative PCR was used to detect DNMT1, SFRP1 and β- catenin mRNA expression in all subjects before chemotherapy and after chemotherapy. Pearson correlation analysis identifies correlations between DNMT1, SFRP1 and β-catenin mRNA levels. All patients were followed up to compare the relationship between DNMT1 and SFRP1 methylation and prognosis. Results The incidence of DNMT1 gene methylation in AML and ALL patients were 26.0% and 25.0%, respectively, which was significantly lower than that in the control group(73.8%) (χ2=47.683, P ＜ 0.001). The methylation rates of SFRP1 gene were 78.0% and 85.0%, respectively, which were significantly higher than those of normal control group (18.5%)(χ2=55.265, P ＜ 0.001), and the differences were statistically significant，respectively. There was significant correlation between DNMT1 methylation and WBC level in AML group and genetic prognosis group (χ2=6.524，5.732, all P ＜ 0.001). The methylation of SFRP1 was significantly correlated with WBC level, BM level and genetic prognosis group (χ2= 8.115, 5.395, 5.060, all P ＜ 0.05). DNMT1 gene methylation was only associated with genetic prognostic grouping in ALL group (χ2=4.802, P ＜ 0.05). The methylation of SFRP1 gene was significantly correlated with WBC level and genetic prognosis (χ2=4.920，5.115, all P ＜ 0.05).Compared with the control group, the mRNA expressions of DNMT1 and β-catenin in AML and ALL patients were significantly increased before chemotherapy (t=4.807 ～ 10.456, all P ＜ 0.05), while the expression of SFRP1 was significantly decreased (t=24.791, 12.069, all P ＜ 0.05). Compared with before chemotherapy, the mRNA expressions of DNMT1 and β-catenin in AML and ALL patients after chemotherapy were significantly decreased (t=3.461 ～ 6.374, all P ＜ 0.05), and the expression of SFRP1 was significantly increased (t=17.076, 7.454, all P ＜ 0.05). There was a significant negative correlation between DNMT1 and SFRP1 expression in two groups (r=-0.328，-0.315, all P ＜ 0.05). SFRP1 was positively correlated with β-catenin expression (r=0.682，0.728, all P ＜ 0.05).There was no significant correlation between DNMT1 and β-catenin expression in two groups. The methylated survival rate of DNMT1 in the two groups was higher than that in the non-methylated survival rate (χ2=3.862, 3.679, all P ＜ 0.05).The methylated survival rate of SFRP1 was lower than that of its unmethylated survival rate (χ2=2.927, 3.155, all P ＜ 0.05). Conclusion The methylation of DNMT1 and SFRP1 was related to the clinicopathology and prognosis of patients with hematological malignancies, and the reason may be related to the abnormal activation of the Wnt/β-catenin signaling pathway by DNMT1 and SFRP1 gene methylation.

参考文献/References:

[1] 郑源海 , 林元峰 , 许瑞元 , 等．急性髓系白血病免疫表型特征与预后相关性分析 [J]．现代检验医学杂志 , 2018, 33(4)：90-94． ZHENG Yuanhai, LIN Yuanfeng, XU Ruiyuan, et al. Correlative analysis of immunophenotypic characteristics and prognosis in acute myeloid leukemia[J]. Journal of Modern Laboratory Medicine,2018,33(4):90-94.
[2] 王玉姣 , 张蕊 , 李艳 .急性髓系白血病中 DNA甲基化异常及相关调控基因的研究进展 [J].现代肿瘤医学 , 2021, 29(19): 3491-3494. WANG Yujiao, ZHANg Rui, LI Yan. Advances in abnormal DNA methylation and related regulatory genes in AML[J]. Journal of Modern Oncology, 2021, 29(19):3491-3494.
[3] BEHZAD M M, SHAHRABI S, JASEB K, et al. Aberrant DNA methylation in chronic myeloid leukemia: cell fate control, prognosis, and therapeutic response[J]. Biochemical Genetics, 2018, 56(3): 149-175.
[4] 黄滔 , 周兴路 , 毛曦轲 , 等 .DNA甲基化基因 DNMT1的研究进展 [J].现代肿瘤医学 , 2019, 27 (14): 2595-2600. HUANG Tao, ZHOU Xinglu, MAO Xike, et al. Advances in research on DNA methylation gene DNMT1[J]. Journal of Modern Oncology, 2019, 27(14):2595-2600.
[5] YU Jun, XIE Yang, LI Mengying, et al. Association between SFRP promoter hypermethylation and different types of cancer: A systematic review and meta-analysis[J]. Oncology Letters, 2019, 18(4): 3481-3492.
[6] BINISZKIEWICZ D, GRIBNAU J, RAMSAHOYE B, et al. Dnmt1 overexpression causes genomic hypermethylation, loss of imprinting, and embryonic lethality[J]. Molecular and Cellular Biology, 2002, 22(7): 2124-2135.
[7] 黄一波 , 王国平 , 王奕 , 等 .胃癌患者 SFRP1, SFRP2, SDC-2 甲基化与病理特征的相关性分析 [J]. 中华全科医学 , 2021, 19(12): 2008-2011. HUANG Yibo, WANG Guoping, WANG Yi, et al. Correlation analysis of SFRP1, SFRP2 and SDC-2 methylation and pathological features in patients with gastric cancer [J]. Chinese Journal of General Practice, 2021, 19(12): 2008-2011.
[8] 沈悌 , 赵永强 , 周道斌 , 等 .血液病诊断及疗效标准 [M].4版 .北京 : 科学出版社 , 2018：91-96. SHEN Ti, ZHAO Yongqiang, ZHOU Daobin, et al. Criteria for diagnosis and efficacy of hematological diseases [M]. 4th Edition. Beijing: Science Press, 2018:91-96.
[9] BAI Yi, WEI Chunlian, ZHONG Yuxin, et al. Development and validation of a prognostic nomogram for gastric cancer based on DNA methylation driven differentially expressed genes[J]. International Journal of Biological Sciences, 2020, 16(7): 1153-1165.
[10] 刘文静 , 王舒婕 , 张巧 , 等．DNA去甲基化在恶性肿瘤中的研究进展 [J].生命的化学 , 2020, 40(11): 2035-2042. LIU Wenjing, WANG Shujie, ZHANG Qiao, et al. Research progress of DNA demethylation in malignant tumors [J]. Chemistry of Life,2020,40(11):2035-2042.
[11] ZHANG Rui, ZHANG Yan, LU Xianglan, et al. SPRED1 is downregulated and a prognostic biomarker in adult acute myeloid leukemia [J]. Front Oncol,2020, 10:204.
[12] 刘晓 , 刘珊 , 李英华 .慢性髓性白血病患者外周血细胞中 SHP-1,DNMTs 水平变化及其与疾病进展的关系 [J].山东医药 , 2018, 58(45): 84-86. LIU Xiao, LIU Shan, LI Yinghua. Changes of SHP-1 and DNMTs levels in peripheral blood cells of patients with chronic myeloid leukemia and their relationship with disease progression [J]. Shandong Medical Journal,2018, 58(45) : 84-86.
[13] VAZ M, HWANG S Y, KAGIAMPAKIS I, et al. Chronic cigarette smoke-induced epigenomic changes precede sensitization of bronchial epithelial cells to single-step transformation by KRAS mutations[J]. Cancer Cell, 2017, 32(3): 360-376, e6.
[14] 吴圣豪 , 陈松燕 , 石岳坚 , 等 .DNA甲基转移酶 DNMT1与 EZH2在急性髓系白血病中的表达及相关性研究 [J].医学研究杂志 , 2016, 45(4): 94-97. WU Shenghao, CHEN Songyan, SHI Yuejian, et al. Relationship between DNMT1 and EZH2 gene expression and clinical significance in patients with acute myeloid leukemia [J]. Journal of Medical Research,2016,45(4):94-97.
[15] PENG Yaojun, WU Qiyan, WANG Lingxiong, et al. A DNA methylation signature to improve survival prediction of gastric cancer[J]. Clinical Epigenetics, 2020, 12(1): 15.
[16] 周碧 , 高吉照．儿童急性淋巴细胞白血病中 sFRP1基因的表达与预后 [J].中国小儿血液与肿瘤杂志 , 2022, 27(1): 45-48. ZHOU Bi, GAO Jizhao. The prognostic value of sFRP1 mRNA expression for acute lymphoblastic leukemia of childhood [J]. Journal of China Pediatric Blood and Cancer,202,27(1):45-48.
[17] 徐成波 , 冯敏 , 廖斌 , 等 .急性白血病细胞系中 SFRP基因启动子甲基化及去甲基化诱导表达的研究 [J].中国病理生理杂志 , 2013, 29(8): 1447-1451. XU Chengbo, FENG Min, LIAO Bin, et al. Promoter methylation status and demethylation-induced expression of SFRP genes in human acute leukemia cell lines [J]. Chinese Journal of Pathophysiolo gy,2013,29:1447-1451.
[18] LIU Xinyan, FU Jinming, BI Haoran, et al. DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients[J]. BMC Cancer, 2019, 19(1): 1212.
[19] 林娜 , 富威 , 李艳 , 等 .急性淋巴细胞白血病中 DNA甲基转移酶 3A剪切体的表达 [J].现代肿瘤医学 , 2018, 26(20): 3180-3183. LIN Na, FU Wei, LI Yan, et al. Expression of DNMT3A transcripts in acute lymphoblastic leukemia [J]. Journal of Modern Oncology,2018,26(20):3180-3183.
[20] JEZIORSKA D M, MURRAY R, DE GOBBI M, et al. DNA methylation of intragenic CpG islands depends on their transcriptional activity during differentiation and disease[J]. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114(36): E7526-E7535.
[21] CHATTERJEE A, PAUL S, BISHT B, et al. Advances in targeting the WNT/β-catenin signaling pathway in cancer[J]. Drug Discovery Today, 2022, 27(1): 82-101.
[22] LI Yandong, L? Zhen, ZHU Weifang. RBBP4 promotes colon cancer malignant progression via regulating Wnt/β-catenin pathway[J]. World Journal of Gastroenterology, 2020, 26(35): 5328-5342.

相似文献/References:

[1]朱理平a,朱理佳,王永志a,等.526 例恶性血液病初诊患者血浆凝血等指标检测的临床意义分析[J].现代检验医学杂志,2020,35(01):105.[doi:10.3969/j.issn.1671-7414.2020.01.028]
　HU Li-pinga,ZHU Li-jia,WANG Yong-zhia,et al.Clinical Significance Analysis of Detection of Plasma Coagulation and Other Indicators in 526 Patients with Newly Diagnosed Malignant Blood Disease[J].Journal of Modern Laboratory Medicine,2020,35(06):105.[doi:10.3969/j.issn.1671-7414.2020.01.028]

备注/Memo

备注/Memo:
基金项目：河北省医学科学研究科研项目(1723021282)。
作者简介：陈莉(1987-)，女，硕士，主治医师，研究方向：血液病诊治，E-mail：UR11888@163.com。
通讯作者：索晓慧(1974-)，男，医学硕士，主任医师，血液内科，E-mail：linsuo@163.com。
更新日期/Last Update: 2022-11-15